ArticleCureus2026
When Type 2 Diabetes Isn't Type 2: Latent Autoimmune Diabetes in a Lean, Highly Physically Active Adult.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable machine learning model for in-hospital hypoglycemia risk in patients with latent autoimmune diabetes in adults.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latent autoimmune diabetes in adults (LADA) is frequently misclassified as type 2 diabetes mellitus (T2DM), leading to delayed diagnosis and suboptimal management. We report a lean, highly physically active adult engaged in sustained, high-intensity physical activity as part of his occupation, in his early 70s, with a 30-year history of presumed T2DM who was referred for endocrine evaluation because of persistent glycemic instability despite insulin therapy. He reported frequent symptomatic episodes of both hyperglycemia and hypoglycemia, resulting in significant occupational stress, as maintenance of physical fitness and body weight was essential for continued employment. Hemoglobin A1c (HbA1c) values remained persistently elevated, ranging from 7.8% to 9.6% (reference range: 3.8%-5.6%), with marked glycemic variability and failure to achieve stable control. Given his low body mass index (BMI) of 20 kg/m² (reference range: 18.5-24.9 kg/m²) and pronounced glucose fluctuations, evaluation for autoimmune diabetes was pursued. Laboratory testing demonstrated markedly elevated glutamic acid decarboxylase (GAD65) antibodies (204 IU/mL; reference range <5 IU/mL) and a low C-peptide level (0.54 ng/mL; reference range 1.10-5.50 ng/mL), confirming LADA with advanced beta-cell failure. Management was transitioned from empiric multiple daily insulin injections to a tubeless automated insulin delivery (AID) system integrated with continuous glucose monitoring (CGM). Over longitudinal follow-up, glycemic control improved substantially, with reduced variability and minimal hypoglycemia. At the most recent follow-up, HbA1c was 6.8% (reference range: 3.8%-5.6%). CGM demonstrated a mean glucose of 153 mg/dL, consistent with CGM-derived targets corresponding to an estimated HbA1c <7% (goal <154 mg/dL), with 74% time-in-range (70-180 mg/dL) and less than 2% time below range (<70 mg/dL). This case highlights key clinical clues for recognizing LADA in adults initially labeled as having T2DM and underscores the importance of timely diagnosis and technology-enabled therapy, particularly in individuals with occupationally demanding physical activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.